Capricor Therapeutics to Hold First Quarter 2015 Business Update and Financial Results Conference Call on May 12, 2015 at 4:30 p.m. EDT

LOS ANGELES, May 5, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (Nasdaq:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that company management will hold a conference call to discuss first quarter 2015 business highlights and financial results at 4:30 p.m. EDT, May 12, 2015.

Access to the live webcast and teleconference is provided below:

• Domestic dial-in: 1-877-407-4018
• International dial-in: 1-201-689-8471
• Webcast: http://capricor.com/investors/

A telephone replay of the call will be available by dialing 877-870-5176 for domestic callers or 858-384-5517 for international callers and entering the conference code: 13608442. The conference call webcast will be archived for approximately 90 days and will be available at http://capricor.com/investors/.

About Capricor Therapeutics

Capricor Therapeutics, Inc. (Nasdaq:CAPR) is a clinical-stage biotechnology company with expertise in the field of cardiovascular disease aiming to develop novel therapies for diseases with tremendous unmet medical needs. Our lead programs target post myocardial infarction (heart attack), heart failure and Duchenne muscular dystrophy. The Company has two leading product candidates under investigation: Cenderitide, a natriuretic peptide receptor agonist, and CAP-1002, a cardiac cell therapy. Cenderitide is in development for the outpatient treatment of heart failure as well as potential other indications. CAP-1002 is in development for the treatment of post myocardial infarction (heart attack), advanced heart failure and Duchenne muscular dystrophy cardiomyopathy. In addition, the Company is conducting research and development on its exosomes platform technology for cardiac diseases and other potential indications. For additional information visit www.capricor.com.

CONTACT: Corporate Contact

         Capricor Therapeutics, Inc.
         AJ Bergmann, Vice President of Finance
         +1-310-358-3200
         abergmann@capricor.com

         Media Relations
         Russo Partners
         Christopher Hippolyte
         +1-646-942-5634
         chris.hippolyte@russopartnersllc.com

         Tony Russo, Ph.D.
         +1-212-845-4251
         tony.russo@russopartnersllc.com

         Investor Relations:
         Russo Partners
         Robert Flamm, Ph.D.
         +1-212-845-4226
         robert.flamm@russopartnersllc.com

Released May 5, 2015